Lisata Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
$LSTA
Misc Health and Biotechnology Services
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
(Address of Principal Executive Offices)(ZipCode)
(908 ) 842-0100
Registrant's telephone number, including area code
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
The | ||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events.
On July 15, 2025, Lisata Therapeutics, Inc. (the “Company”) announced that it has been issued a patent from the United States Patent and Trademark Office (“USPTO”) covering the composition of matter of certepetide, more specifically, around its chemical structure and pharmacokinetic properties. The granted patent, U.S. Patent No. 12,351,653, further expands the Company’s intellectual property estate around certepetide and will expire in March 2040. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference.
A copy of the electronic grant (eGrant) notification and patent certificate are attached to this Current Report as Exhibit 99.2 and is incorporated herein solely for purposes of this Item 8.01 disclosure.
Item 9.01. Financial Statement and Exhibits.
(d) Exhibits
| Exhibit No. | Description | ||||
| Press Release, dated July 15, 2025 | |||||
| Electronic grant (eGrant) notification and patent certificate of U.S. Patent No. 12,351,653, titled “PHARMACEUTICAL COMPOSITIONS COMPRISING NOVEL CYCLIC PEPTIDES,” issued on July 8, 2025 | |||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LISATA THERAPEUTICS, INC.
By: /s/ David J. Mazzo
Name: David J. Mazzo, PhD
Title: President & Chief Executive Officer
Dated: July 15, 2025